Literature DB >> 2867204

Relationship between alpha adrenoceptor occupancy and response for the alpha-1 adrenoceptor agonist, cirazoline, and the alpha-2 adrenoceptor agonist, B-HT 933, in canine saphenous vein.

R R Ruffolo, R L Zeid.   

Abstract

The relationship between alpha adrenoceptor occupancy and response was investigated for the alpha-1 adrenoceptor agonist, cirazoline, and the alpha-2 adrenoceptor agonist, B-HT 933, in canine saphenous vein, a tissue known to contain both alpha adrenoceptor subtypes. Both cirazoline and B-HT 933 produced dose-dependent vasoconstrictor responses in canine saphenous vein, with the maximum vasoconstrictor response elicited by B-HT 933 being only 75% of that produced by cirazoline. Dissociation constants were obtained for cirazoline (0.61 microM) and B-HT 933 (4.99 microM) for interaction with postsynaptic vascular alpha-1 and alpha-2 adrenoceptors, respectively, by the method of fractional irreversible receptor inactivation using phenoxybenzamine. Based on this information, alpha-1 and alpha-2 adrenoceptor occupancy-response relationships were constructed. The alpha-1 adrenoceptor occupancy-response relationship obtained for cirazoline was approximately 4-fold more favorable than the alpha-2 adrenoceptor occupancy-response relationship for B-HT 933, although both agonists were associated with a significant receptor reserve. The alpha-1 adrenoceptor occupancy-response relationship of cirazoline and the alpha-2 adrenoceptor occupancy-response relationship of B-HT 933 were both rectangular hyperbolas, suggesting that both compounds have high intrinsic efficacy at their respective alpha adrenoceptor subtypes. The results indicate that a receptor reserve exists for the alpha-1 and alpha-2 adrenoceptor-mediated effects of cirazoline and B-HT 933, respectively, and that the alpha adrenoceptor reserve may be significantly larger for postsynaptic vascular alpha-1 adrenoceptors than for postsynaptic vascular alpha-2 adrenoceptors in canine saphenous vein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867204

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  An attempt at selective protection from phenoxybenzamine of postjunctional alpha-adrenoceptor subtypes mediating contractions to noradrenaline in the rabbit isolated saphenous vein.

Authors:  C J Daly; W R Dunn; J C McGrath; V G Wilson
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

2.  Postsynaptic alpha-adrenoceptor reserve and the shift of the concentration-response curves to the right, as caused by the irreversible alpha-adrenoceptor antagonist phenoxybenzamine.

Authors:  S Guimarães; M Q Paiva
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

3.  Alpha-adrenoceptor subtypes in dog saphenous vein that mediate contraction and inositol phosphate production.

Authors:  P E Hicks; M Barras; G Herman; P Mauduit; J M Armstrong; B Rossignol
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

4.  The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonist.

Authors:  C M Brown; A C MacKinnon; W S Redfern; P E Hicks; A T Kilpatrick; C Small; M Ramcharan; R U Clague; R D Clark; C B MacFarlane
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

5.  Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes.

Authors:  K Horie; K Obika; R Foglar; G Tsujimoto
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

6.  Extended concentration-response curves used to reflect full agonist efficacies and receptor occupancy-response coupling ranges.

Authors:  M J Lew
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

7.  Pharmacologic differentiation between pre- and postjunctional alpha 2-adrenoceptors by SK&F 104078.

Authors:  R R Ruffolo; A C Sulpizio; A J Nichols; R M DeMarinis; J P Hieble
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.